SCHEMBL1507696

SCHEMBL1507696

O=C(Nc1cccc2cccnc12)c1cccc2cccnc12

nearest known ligand 0.78

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.78
KDM4E B2RXH2 1/20 0.78
SMN1; SMN2 Q16637 1/20 0.78
KDR P35968 6/20 0.76
MEN1 O00255 4/20 0.71
KMT2A Q03164 4/20 0.71
RAB9A P51151 3/20 0.71
L3MBTL1 Q9Y468 3/20 0.67
HDAC6 Q9UBN7 1/20 0.67
PLEC Q15149 1/20 0.67
TDP1 Q9NUW8 3/20 0.65
NPC1 O15118 2/20 0.65
GAA P10253 1/20 0.65
HTT P42858 1/20 0.65
CASP3 P42574 1/20 0.65
SENP8 Q96LD8 1/20 0.65
SENP7 Q9BQF6 1/20 0.65
SENP6 Q9GZR1 1/20 0.65
POLB P06746 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6796051 0.91 MAPT (0.66) MAPTKDM4ESMN1; SMN2KDRMEN1
SCHEMBL27803982 0.89 MAPT (0.72) MAPTKDM4ESMN1; SMN2KDRMEN1
SCHEMBL29832141 0.88 MAPT (1.00) MAPTKDM4ESMN1; SMN2KDRMEN1
SCHEMBL27782316 0.88 MAPT (0.71) MAPTKDM4ESMN1; SMN2KDRMEN1
SCHEMBL12172758 0.88 MAPT (0.75) MAPTKDM4ESMN1; SMN2KDRMEN1
SCHEMBL19422863 0.88 MAPT (1.00) MAPTKDM4ESMN1; SMN2KDRMEN1
SCHEMBL27782344 0.88 KDR (0.78) MAPTKDM4ESMN1; SMN2KDRMEN1
SCHEMBL11995708 0.87 MAPT (0.73) MAPTKDM4ESMN1; SMN2KDRMEN1
SCHEMBL28517267 0.87 RAB9A (0.65) MAPTKDM4ESMN1; SMN2KDRMEN1
SCHEMBL29510019 0.87 KDR (1.00) MAPTKDM4ESMN1; SMN2KDRMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090227626-A1 NOVEL POLYQUINOLINE DERIVATIVES AND THERAPEUTIC USE THEREOF PALUMED S.A. (FR) 2009-09-10 US claimed
EP-1919894-B1 NOVEL POLYQUINOLINE DERIVATIVES AND THE THERAPEUTIC USE THEREOF PALUMED SA (FR) 2014-10-08 EP disclosed
US-8324196-B2 Polyquinoline derivatives and the therapeutic use thereof PALUMED S.A. (FR) 2012-12-04 US disclosed
US-20120277265-A1 NOVEL POLYQUINOLINE DERIVATIVES AND THE THERAPEUTIC USE THEREOF CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.) (FR) 2012-11-01 US disclosed
US-8247396-B2 Polyquinoline derivatives and therapeutic use thereof PALUMED S.A. (FR) 2012-08-21 US disclosed
EP-2289891-A2 Novel polyquinoline derivates and the therapeutic use thereof Palumed S.A. (FR) 2011-03-02 EP disclosed
US-20090227626-A1 NOVEL POLYQUINOLINE DERIVATIVES AND THERAPEUTIC USE THEREOF PALUMED S.A. (FR) 2009-09-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120277265-A1 NOVEL POLYQUINOLINE DERIVATIVES AND THE THERAPEUTIC USE THEREOF HTT, APP, PSEN1 MAPT 14/4885KDM4E 4293/4885SMN1; SMN2 315/4885
US-20090227626-A1 NOVEL POLYQUINOLINE DERIVATIVES AND THERAPEUTIC USE THEREOF HTT, UBQLN2, UBQLN1 MAPT 235/4885KDM4E 3878/4885SMN1; SMN2 118/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.